Lori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion positive, and RET–altered disease; and optimal therapies for patients with multiple types of thyroid cancer.
Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based r...
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the many considerations when caring for patients with head and neck cancers, such as dental and nut...
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, and Mary F. Mulcahy, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University,...
Shivan J. Mehta, MD, MBA, of Abramson Cancer Center at the University of Pennsylvania, discusses how insights from behavioral economics could be harnessed to improve HPV vacc...
